R&D News | pharmaphorum

News

Boehringer, Lilly face off in MASH at EASL

Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa

News

Last places on FDA START rare disease programme filled

The last three slots for projects that will be included in the FDA’s new programme to accelerate the development of therapies for rare diseases have been taken by Moderna,

News

Telix prices $200m IPO in big week for radiopharma financing

Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio

News

Buoyed by new obesity data, Structure files $476m offering

Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million

News

Amgen preps Uplizna filing for a second indication

Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, a

News

Mexican man dies in first human case of H5N2 bird flu

A man in Mexico has died in what the World Health Organization (WHO) has said is the first lab-confirmed human infection with the H5N2 strain of bird flu.

Boehringer, Lilly face off in MASH at EASL

Last places on FDA START rare disease programme filled

Telix prices $200m IPO in big week for radiopharma financing

Buoyed by new obesity data, Structure files $476m offering

Amgen preps Uplizna filing for a second indication

Mexican man dies in first human case of H5N2 bird flu

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks